Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice

I Seul Park; Mijeong Son; Hyun Woo Ma; Jihyung Kim; Da Hye Kim; Seung Won Kim; Jae Hee Cheon

doi:10.5217/ir.2020.00075

Articles

Page Path: HOME > Intest Res > Volume 19(3); 2021 > Article

Brief Communication Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice: I Seul Park^1,2, Mijeong Son^1,2, Hyun Woo Ma^1,2, Jihyung Kim^1,2, Da Hye Kim¹, Seung Won Kim^1,2,3,, Jae Hee Cheon^1,2,3,; Intestinal Research 2021;19(3):349-353.
DOI: https://doi.org/10.5217/ir.2020.00075
Published online: November 2, 2020

¹Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

²Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea

³Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea

Correspondence to Jae Hee Cheon, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: +82-2-2228-1990, Fax: +82-2-393-6884, E-mail: GENIUSHEE@yuhs.ac

Co-Correspondence to Seung Won Kim, Severance Biomedical Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemungu, Seoul 03722, Korea. Tel: +82-2-2228-0788, Fax: +82-2-2228-2812, E-mail: swk21c@hanmail.net

• Received: June 23, 2020 • Revised: July 24, 2020 • Accepted: July 25, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

5,589 Views
168 Download
8 Web of Science
8 Crossref
8 Scopus

Full Article

Download PDF

NOTES
REFERENCES

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic and inappropriate inflammatory disorder of the intestine. It is considered that interactions between genetic factors, microbiota, and host immune system are involved in the pathogenesis of IBD. Particularly, recent studies have shown that metabolites from intestinal microbes or host modulate the immune system in colitis [1]. This study focused on macrophages and the role of succinate as an anti-inflammatory metabolite in IBD. Macrophages exist in almost all organs and are responsible for the first line of antimicrobial defense [1]. The macrophages can be divided into pro-inflammatory M1 macrophages, called “classical macrophage,” and anti-inflammatory M2 macrophages, called “alternative macrophage.” It was reported that switching between M1 and M2 macrophages occurs through metabolic changes. In M2 macrophages, the succinate is oxidized to fumarate, resulting in electron transport chain flow that provides energy for adenosine triphosphate synthase. On the other hand, reverse electron transport occurs and succinate is accumulated in M1 macrophages [2,3]. If the polarization of macrophages is not properly regulated, this increases the proportion of M1 macrophages and can affect disease development such as IBD [4].

Although there is a prior study using trinitrobenzene sulfonic acid-induced colitis and focusing on succinate receptor 1 (SUCNR1) and fibrosis [5], it is not yet clear whether succinate directly affects macrophage activity in colitis. Wang et al. [6] showed macrophages from peritoneal cavity cells (PCCs) affect experimental colitis. Hence, to identify the direct effect of succinate on macrophages, we performed a transfer experiment to find out the effects of succinate on macrophages in a dextran sulfate sodium (DSS) (MP Biomedicals, Solon, OH, USA)-induced colitis model (Fig. 1A). All experiments using animals were reviewed and approved by the Institutional Animal Care and Use Committee of Yonsei University Severance Hospital (IACUC No: 2018-0227), and all methods were performed in accordance with relevant guidelines and regulations. Eight-weekold male C57BL/6 mice were maintained in 12 hours light/12 hours dark cycle at 22°C under specific pathogen‐free conditions and used as donors of peritoneal macrophages. The following groups of mice were used as donors: injected vehicle (Veh) (n = 4); injected succinate (Suc) (n = 4). F4/80⁺ peritoneal macrophages were isolated using BD FACS Aria II (BD Biosciences, San Jose, CA, USA) from the collected peritoneal cells of mice which were then intraperitoneally injected with 40 mM succinate or not for 3 days (Fig. 1B and C). Isolated F4/80⁺ cells of 2 × 10⁵ were intraperitoneally injected to recipient mice in 200 μL Hanks’ balanced salt solution (HBSS; Thermo Fisher Scientific, Inc., Waltham, MA, USA) (day 0) and the mice were sacrificed after 2% (wt/vol) DSS in drinking water until day 6 followed by normal water administrated for 2 days. Recipient groups were as follows: water, administered with normal water (n = 3); DSS+HBSS, administered with HBSS (n = 6); DSS+VehPCC, recipients of PCC (n = 4); DSS+Suc-PCC, recipients of PCC treated succinate (n = 4). To estimate the severity of colitis, body weight, and disease activity index (DAI) were checked daily. The DAI scores, which ranged from 0 to 4, were calculated using the following parameters: body weight loss (0, none; 1, 1%–5%; 2, 5%–10%; 3, 10%–20%; 4, > 20%), stool consistency (0, negative; 1 and 2, loose; 3 and 4, diarrhea), and bleeding (0, absence; 1 and 2, slightly bleeding; 3 and 4, bloody) [7]. The calculated formula was as follows: DAI = (body weight loss score)+ (stool consistency score)+(bleeding score). The colon length was measured between the ileocecal junction and the proximal rectum.

DSS+Suc-PCC mice showed the attenuated body weight loss (Fig. 2A), DAI (Fig. 2B), and a colon length shortening (Fig. 2C) compared with DSS+Veh-PCC mice. For histological analysis, segments of distal colons were embedded in paraffin and stained with periodic acid‐Schiff to observe goblet cells and mucins. We found that mucin levels were significantly increased in succinate-treated PCC group compared with DSS+Veh-PCC group (Fig. 3). Taken together, these results suggest that succinate-treated PCC attenuates DSS-induced colitis.

Although some researches on succinate have mainly described succinate as a pro-inflammatory factor in many inflammatory diseases [8], there are contradictory studies that succinate acts as an anti-inflammatory factor [9,10]. The succinate secreted by the cancer cells into their microenvironment induces polarization into tumor-associated macrophages through SUCNR1 signaling of macrophages [9]. Besides, another study showed that SUCNR1 on macrophages plays a role in inducing antiinflammatory phenotype and limiting inflammation [10]. These controversial results showing pro- and anti-inflammatory effects of succinate might be due to the complexity of the immune system. In this study, we addressed the protective function of succinate in macrophages.

It is well known that succinate dehydrogenase is impaired in inflammatory conditions, and then succinate is accumulated. Further studies investigating the effects of succinate on various macrophages types, using cell lines and primary cells from Sucnr1^-/- mice would be warranted.

NOTES

Funding Source

This work was supported by Mid-career Researcher Program through NRF grant funded by the Korea government (MSIP) (NRF-2017R1A2B4001848) and by the Research Program funded by the Korea Centers for Disease Control and Prevention (2019-ER6905-01).

Conflict of Interest

Cheon JH is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Author Contribution

Conceptualization: Kim SW, Cheon JH. Data curation: Park IS, Kim SW, Ma HW. Formal analysis: Park IS, Son M. Funding acquisition: Cheon JH. Investigation: Park IS, Son M, Kim J. Methodology: Kim SW, Kim DH, Ma HW. Project administration: Kim SW, Cheon JH. Resources: Kim SW, Cheon JH. Software: Park IS, Kim SW. Supervision: Kim SW, Cheon JH. Validation: Kim SW, Cheon JH. Visualization: Park IS. Writing – original draft: Park IS. Writing – review & editing: Kim SW, Cheon JH. Approval of final manuscript: all authors.

Fig. 1.

Peritoneal cavity cell transfer in a dextran sulfate sodium (DSS)-colitis model. (A) Experimental design of the peritoneal cavity cells (PCCs) transfer. Donor mice were intraperitoneally injected with 40 mM succinate or not for 3 days. Recipient mice were transferred with the PCCs on day 0, were then administrated 2% DSS in drinking water until day 6 followed by normal water for 2 days and were sacrificed on day 8. (B, C) Gating strategy of peritoneal macrophage sorting. F4/80⁺ PCCs isolation using BD FACS Aria II. (B) Unstained PCCs. (C) Stained pre-sorting PCCs and post-sorting PCCs. HBSS, Hanks’ balanced salt solution; Veh, vehicle; Suc, succinate; SSC-A, side-scatter area; FSC-A, forward-scatter area; FSC-W, forward-scatter width; FSC-H, forward-scatter height; SSC-W, side-scatter width; SSC-H, sidescatter height; WT, water.

Fig. 2.

Transferred succinate-treated peritoneal cavity cells (Suc-PCCs) ameliorate dextran sulfate sodium (DSS)-induced colitis. The recipients of Suc-PCCs show the attenuated body weight change (A), disease activity index (DAI) (B), and colon length (C) compared to vehicle-treated PCC (Veh-PCC). The results were examined using Prism 5.0 software (GraphPad Inc.). Statistical significance was evaluated using one-way analysis of variance and P<0.05 were regarded to be significant. Bars in graphs represent mean±standard error of the mean. ^aP<0.05, ^bP<0.01, and ^cP<0.001 compared with the water group. ^dP<0.05, ^eP<0.01, and ^fP<0.001 compared with the Suc-PCC group. HBSS, Hanks’ balanced salt solution.

Fig. 3.

Periodic acid Schiff staining and quantification of colitis. (A) Section from colon tissues stained with periodic acid Schiff. Histopathologic scores (B) and quantification with integrated density (IntDen) of goblet cells (C) of colon tissues from mice were assessed by Image J v.1.496 software (National Institutes of Health). The results were examined using Prism 5.0 software (GraphPad Inc.). Statistical significance was evaluated using one-way analysis of variance and t-test, respectively, P<0.05 were considered significant. Bars in graphs represent mean±standard error of the mean. ^aP<0.05, ^bP<0.001 compared with the water group in (B). DSS, dextran sulfate sodium; HBSS, Hanks’ balanced salt solution; PCC, peritoneal cavity cell; Veh, vehicle; Suc, succinate.

REFERENCES

1. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 2019;569:655–662.Article PubMed PMC PDF
2. Diskin C, Pålsson-McDermott EM. Metabolic modulation in macrophage effector function. Front Immunol 2018;9:270.Article PubMed PMC
3. Viola A, Munari F, Sánchez-Rodríguez R, Scolaro T, Castegna A. The metabolic signature of macrophage responses. Front Immunol 2019;10:1462.Article PubMed PMC
4. Mizoguchi E, Low D, Ezaki Y, Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intest Res 2020;18:151–167.Article PubMed PMC PDF
5. Macias-Ceja DC, Ortiz-Masiá D, Salvador P, et al. Succinate receptor mediates intestinal inflammation and fibrosis. Mucosal Immunol 2019;12:178–187.Article PubMed PDF
6. Wang W, Li X, Zheng D, et al. Dynamic changes of peritoneal macrophages and subpopulations during ulcerative colitis to metastasis of colorectal carcinoma in a mouse model. Inflamm Res 2013;62:669–680.Article PubMed PDF
7. Seo DH, Che X, Kwak MS, et al. Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. Sci Rep 2017;7:851.Article PubMed PMC PDF
8. Connors J, Dawe N, Van Limbergen J. The role of succinate in the regulation of intestinal inflammation. Nutrients 2018;11:25.Article PubMed PMC
9. Wu JY, Huang TW, Hsieh YT, et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol Cell 2020;77:213–227.Article PubMed
10. Keiran N, Ceperuelo-Mallafré V, Calvo E, et al. SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity. Nat Immunol 2019;20:581–592.Article PubMed PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention
Hong Huang, Gejing Li, Yini He, Jing Chen, Jianye Yan, Qin Zhang, Liqing Li, Xiong Cai
Frontiers in Immunology.2024;[Epub] CrossRef
Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
Ji Hyung Kim, Jee In Yoo, Hyun Woo Ma, I Seul Park, Mijeong Son, Yoojin Shin, Ki Beom Kim, Seung Won Kim, Si Jae Park, Jihye Park
Intestinal Research.2023; 21(2): 266. CrossRef
Succinate metabolism and its regulation of host-microbe interactions
Yi-han Wei, Xi Ma, Jiang-chao Zhao, Xiu-qi Wang, Chun-qi Gao
Gut Microbes.2023;[Epub] CrossRef
Urolithin A Alleviates Colitis in Mice by Improving Gut Microbiota Dysbiosis, Modulating Microbial Tryptophan Metabolism, and Triggering AhR Activation
Mingxia Ma, Yanxin Wang, Siqing Fan, Yumeng Huang, Xiurong Su, Chenyang Lu
Journal of Agricultural and Food Chemistry.2023; 71(20): 7710. CrossRef
Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
Gut and Liver.2023; 17(5): 766. CrossRef
Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
Gut and Liver.2023; 17(6): 905. CrossRef
Microbial Modulation in Inflammatory Bowel Diseases
Jongwook Yu, Jae Hee Cheon
Immune Network.2022;[Epub] CrossRef
Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
Intestinal Research.2021; 19(4): 478. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice

Intest Res. 2021;19(3):349-353. Published online November 2, 2020

DOI: https://doi.org/10.5217/ir.2020.00075

XML Download

Figure

Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice

Fig. 1. Peritoneal cavity cell transfer in a dextran sulfate sodium (DSS)-colitis model. (A) Experimental design of the peritoneal cavity cells (PCCs) transfer. Donor mice were intraperitoneally injected with 40 mM succinate or not for 3 days. Recipient mice were transferred with the PCCs on day 0, were then administrated 2% DSS in drinking water until day 6 followed by normal water for 2 days and were sacrificed on day 8. (B, C) Gating strategy of peritoneal macrophage sorting. F4/80+ PCCs isolation using BD FACS Aria II. (B) Unstained PCCs. (C) Stained pre-sorting PCCs and post-sorting PCCs. HBSS, Hanks’ balanced salt solution; Veh, vehicle; Suc, succinate; SSC-A, side-scatter area; FSC-A, forward-scatter area; FSC-W, forward-scatter width; FSC-H, forward-scatter height; SSC-W, side-scatter width; SSC-H, sidescatter height; WT, water.

Fig. 2. Transferred succinate-treated peritoneal cavity cells (Suc-PCCs) ameliorate dextran sulfate sodium (DSS)-induced colitis. The recipients of Suc-PCCs show the attenuated body weight change (A), disease activity index (DAI) (B), and colon length (C) compared to vehicle-treated PCC (Veh-PCC). The results were examined using Prism 5.0 software (GraphPad Inc.). Statistical significance was evaluated using one-way analysis of variance and P<0.05 were regarded to be significant. Bars in graphs represent mean±standard error of the mean. aP<0.05, bP<0.01, and cP<0.001 compared with the water group. dP<0.05, eP<0.01, and fP<0.001 compared with the Suc-PCC group. HBSS, Hanks’ balanced salt solution.

Fig. 3. Periodic acid Schiff staining and quantification of colitis. (A) Section from colon tissues stained with periodic acid Schiff. Histopathologic scores (B) and quantification with integrated density (IntDen) of goblet cells (C) of colon tissues from mice were assessed by Image J v.1.496 software (National Institutes of Health). The results were examined using Prism 5.0 software (GraphPad Inc.). Statistical significance was evaluated using one-way analysis of variance and t-test, respectively, P<0.05 were considered significant. Bars in graphs represent mean±standard error of the mean. aP<0.05, bP<0.001 compared with the water group in (B). DSS, dextran sulfate sodium; HBSS, Hanks’ balanced salt solution; PCC, peritoneal cavity cell; Veh, vehicle; Suc, succinate.

Fig. 1.

Fig. 2.

Fig. 3.

Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice